Hans Lehrach to Present on Big Data Medicine at GTC’s Biomarker Europe Summit, Oct. 9-10, Berlin

Monrovia, CA, July 26, 2013 --(PR.com)-- Hans Lehrach, Director of the Max Planck Institute for Molecular Genetics will give a presentation titled “Big Data Medicine and Drug Development” at GTC’s Biomarker Summit Europe on October 9–10, 2013 in Berlin, Germany.

In the last ten or so years, Dr. Lehrach’s lab has developed systems biology approaches, which they expect to be able to close the gap from deriving insights and data by both small scale and large scale analysis techniques. The ultimate goal is to be able to make medically relevant predictions from data generated on individual patients, based on a combination of second generation sequencing techniques with large scale modelling of the network of cancer relevant pathways in the individual tumour. Due to dramatic progress in sequencing techniques, as well as the modelling approaches, they expect this to become essential steps towards an individualised therapy for cancer and other important diseases.

Dr. Lehrach’s presentation will highlight the following points:

• Truly individualized cancer treatment
• Drug development
• Virtualisation of drugs
• More drugs at lower costs
• Biomarker identification

GTC’s Biomarker Europe 2013 will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, companion diagnostics, next-generation sequencing technologies, regulatory and reimbursement issues and companion diagnostics.

For more information, please visit www.gtcbio.com/biomarkerseuro